Elacridar (GF120918) Elacridar P-gp inhibitor Reverses ABCB1 Mediated Multidrug Resistance in Cancer
Copy code to add this image to your page
Multidrug resistance (MDR) remains a major barrier to successful cancer chemotherapy. Overexpression of the ATP-binding cassette transporter P-glycoprotein (P-gp/ABCB1) actively extrudes diverse lipophilic chemotherapeutics out of neoplastic cells. This ATP-dependent efflux mechanism significantly lowers intracellular drug concentrations, blunting therapeutic efficacy. Elacridar (GF120918) is a potent, second-generation acridonecarboxamide derivative designed to disable ABCB1 efflux activity. Under tested in vitro assay conditions, the Elacridar P-gp inhibitor engages the transmembrane domain of ABCB1 to block substrate transport cascades. Evaluating benchmark reference inhibitors alongside novel MDR reversing compounds provides essential insights into transport kinetics and biochemical efficacy.
Quantitative transport assays utilizing MDCK-MDR1 cell monolayers demonstrate the strong inhibitory capacity of Elacridar (GF120918). In these polarized cell monolayers, P-gp functions as a primary directional barrier to hydrophobic molecules. Application of Elacridar (GF120918) yields robust, concentration-dependent inhibition of directional transport. Complete P-gp efflux blockade occurs at a concentration of 2 µM under standard assay conditions. The calculated half-maximal inhibitory concentration (IC50) for ABCB1 transport suppression was 0.37 ± 0.08 µM. This baseline metric establishes Elacridar as a benchmark reference inhibitor, superior in potency to early-generation compounds such as Verapamil. Mechanistically, inhibition involves high-affinity target engagement at the drug-binding pocket, preventing substrate trans-inhibition.
Biochemical characterization of P-gp ATPase activity further clarifies the molecular mechanism of action. ABCB1 relies on catalytic ATP hydrolysis at its nucleotide-binding domains (NBDs) to power conformational changes necessary for substrate translocation. Elacridar (GF120918) modulates this basal and verapamil-stimulated ATPase activity. At sub-micromolar levels, the compound uncouples ATP hydrolysis from substrate translocation, trapping the transporter in an inactive non-productive state. Calcein-AM fluorometric assays confirm these biochemical observations in intact cell models. Calcein-AM serves as a non-fluorescent P-gp substrate that rapidly permeates membranes; upon efflux inhibition, intracellular esterases hydrolyze calcein-AM into fluorescent calcein. Treatment with Elacridar (GF120918) results in rapid intracellular accumulation of calcein fluorescence. Intracellular fluorophore accumulation mirrored transport inhibition curves, confirming complete functional blockade of the efflux pump.
Restoring intracellular chemotherapeutic accumulation translates directly into enhanced cytotoxic activity in multidrug-resistant tumor cell lines. ABCB1 substrates include structurally distinct agents such as vinca alkaloids, taxanes, and anthracyclines. Co-administration of Elacridar (GF120918) at non-cytotoxic concentrations significantly enhances the intracellular accumulation and retention of vincristine, paclitaxel, and doxorubicin in resistant cancer cells. In cell viability assays, combination treatment shifts the half-maximal lethal concentration (LC50) of paclitaxel back toward baseline levels observed in drug-sensitive parental lines. Doxorubicin-induced DNA damage signaling and subsequent apoptosis resume following P-gp blockade. Similarly, vincristine-mediated mitotic arrest is restored in resistant populations. These findings confirm that ABCB1 target engagement by Elacridar overcomes established transport-mediated resistance mechanisms, providing a clear experimental benchmark for developing novel MDR reversal agents.
Pharmacological Characterization and MDR Reversal Efficacy
Copy code to add this image to your page
Elacridar (GF120918) acts as a potent, selective inhibitor of the P-glycoprotein (P-gp/ABCB1) efflux transporter. By binding to the transmembrane substrate domain and inhibiting ATP hydrolysis, it prevents the active extrusion of hydrophobic molecules across the cell membrane. In MDCK-MDR1 monolayers and calcein-AM assays, Elacridar demonstrates complete transport blockade at 2 µM with an IC50 of 0.37 ± 0.08 µM. This inhibition restores intracellular concentrations of chemotherapeutics such as vincristine, paclitaxel, and doxorubicin, successfully reversing multidrug resistance in cancer cells.
Complete Efflux Blockade in MDCK-MDR1 Monolayer Transports
Directional transport assays across MDCK-MDR1 cell monolayers provide direct measurement of transepithelial flux. Intracellular drug retention rose sharply upon drug application. Under tested in vitro assay conditions, the Elacridar P-gp inhibitor achieved complete functional blockade of directional substrate transport at 2 µM. The calculated IC50 value reached 0.37 ± 0.08 µM across independent experimental replicates. Non-specific membrane disruption was not observed. By binding directly to the transmembrane domain of ABCB1, the inhibitor disrupts substrate translocation pathways. This high-affinity interaction stops the extrusion of lipophilic compounds, establishing a consistent reference standard for comparative drug evaluation.
Sensitization of Cytotoxic Agents in Resistant Cell Lines
Multidrug resistance severely limits the efficacy of conventional cytotoxic regimens. Chemotherapeutic retention increased within minutes. Co-treatment with the Elacridar P-gp inhibitor restores cell sensitivity to paclitaxel, doxorubicin, and vincristine in ABCB1-overexpressing cell lines. Intracellular accumulation of doxorubicin was verified by fluorescence microscopy. Within this cellular context, combination therapy restored nuclear accumulation of anthracyclines and triggered apoptotic cascades. The cytotoxicity of paclitaxel shifted back to sub-nanomolar ranges typical of parental non-resistant phenotypes. These observations confirm that ABCB1 inhibition effectively circumvents acquired transport resistance mechanisms.
Potent Inhibition of ABCB1 ATPase Hydrolysis Activity
Active efflux by ABCB1 requires energy derived from ATP hydrolysis at dual nucleotide-binding domains. Catalytic activity dropped significantly. Enzymatic assays measuring basal and substrate-stimulated orthophosphate release demonstrated that Elacridar (GF120918) inhibits P-gp ATPase activity at sub-micromolar concentrations. Calcein-AM retention assays supported these biochemical findings in live cell systems. Fluorescence levels peaked rapidly following inhibitor addition. Blocking energy-coupled substrate transport traps the pump in a non-functional state. Consequently, intracellular drug accumulation remains elevated, preventing sub-therapeutic cellular exposure.